Sickle cell vaso-occlusive crisis: workup and management
Vaso-occlusive crisis is the most common reason adults with sickle cell disease come to hospital. Give effective analgesia within an hour using the patient's individualized plan, look for complications (acute chest syndrome, infection, aplastic crisis, stroke, splenic sequestration), and avoid overhydration.
Working diagnosis
Adult · US guidelines
Draft · awaiting physician review
01Orient
What's new in the evidence
- ASH 2020 pain guideline: analgesia within 1 hour of ED arrival with reassessment every 30–60 minutes; individualized opioid dosing; low-dose ketamine and regional anesthesia for refractory pain
- Voxelotor (Oxbryta) was withdrawn from the market worldwide in 2024 for safety concerns
- Gene therapies (exagamglogene autotemcel, lovotibeglogene autotemcel) were FDA-approved in 2023 for eligible patients
Differential diagnoses
- Uncomplicated vaso-occlusive crisis
- Acute chest syndrome (can't miss)
- Sepsis or osteomyelitis (functional asplenia) (can't miss)
- Acute stroke (can't miss)
- Splenic or hepatic sequestration, aplastic crisis (parvovirus B19)
- Priapism, avascular necrosis, cholecystitis, PE, acute abdomen
02Assess
Risk scores and decision tools
- Pain score reassessment every 30–60 minutes
- Acute chest syndrome: new infiltrate plus fever, chest pain, hypoxia or respiratory symptoms
- Reticulocyte count and hemoglobin vs baseline (aplastic crisis, sequestration, hemolysis)
Key history questions
- Pain location and similarity to usual crises; individualized care plan and home analgesics
- Fever, cough, chest pain, dyspnea
- Neurological symptoms, priapism, abdominal pain
- Hydroxyurea and other disease-modifying therapy; transfusion history and alloantibodies
- Baseline hemoglobin
Examination findings
- Vitals including SpO₂ and temperature
- Chest exam (crackles, dullness)
- Spleen and liver size
- Neurological exam; joint and bone tenderness
03Investigate
Initial investigations
- CBC with reticulocytes; compare with baseline
- BMP, LFTs, LDH, bilirubin
- Type and screen (with extended phenotype)
- Chest X-ray if any respiratory symptoms or fever; blood cultures if febrile
Advanced investigations
- CT or MRI brain for neurological symptoms
- Parvovirus B19 testing if reticulocytopenia
- Imaging for osteomyelitis or avascular necrosis
04Treat
Immediate management
- Parenteral opioid within 1 hour, dosed from the individualized plan or home regimen; reassess every 30–60 minutes
- Fever: blood cultures and empiric ceftriaxone
- Oxygen only if SpO₂ <95% or below baseline
First-line treatment
- Scheduled analgesia or PCA with breakthrough doses; add NSAID if renal function allows
- IV fluids only for euvolemia (avoid overhydration, which raises acute chest syndrome risk)
- Incentive spirometry every 2 hours while awake
- VTE prophylaxis; continue hydroxyurea
Second-line treatment
- Opioid-refractory pain: low-dose ketamine infusion (0.1–0.3 mg/kg/h) or regional anesthesia
- Acute chest syndrome: ceftriaxone plus azithromycin, simple transfusion; exchange transfusion if severe
- Avoid transfusing above hemoglobin ~10 g/dL (hyperviscosity)
Specialist referrals
- Hematology or sickle cell team
- ICU for acute chest syndrome with hypoxia
- Neurology for stroke (urgent exchange transfusion)
05Disposition
Admission criteria
- Pain uncontrolled after 2–3 doses of parenteral opioid
- Acute chest syndrome, fever, sequestration, aplastic crisis or stroke
Safe discharge criteria
- Pain controlled on oral analgesia
- No complications; follow-up and refills arranged
Follow-up timing
- Hematology within 1–2 weeks
Patient instructions
- Hydrate, rest, use home pain plan
- Return for fever, chest pain, breathlessness, weakness or priapism >2–4 hours
Monitoring
- Pain and sedation scores
- SpO₂ continuously while on opioids
- Daily CBC and reticulocytes
Clinical pearls and pitfalls
- Patients often describe stigma and delays; the guideline emphasizes timely, trusting care
- Fever in sickle cell disease is a medical emergency because of functional asplenia
- Use extended-phenotype matched blood to reduce alloimmunization
RefGuidelines and landmark evidence
For education only. Typical adult starting points; confirm doses against renal function, allergies, interactions and your institution's protocols. Not a substitute for clinical judgment or senior review.